A panel of breast oncologists define chemotherapy-induced neutropenia in terms of how they assess risk and attempt to prevent treatment-related toxicities in patients with cancer.

Current recommendations by the National Comprehensive Cancer Network on chemotherapy-induced neutropenia prophylaxis, with special considerations for managing patients with cancer during COVID-19.

Variables that oncologists should consider when determining when to initiate prophylactic therapy for chemotherapy-induced neutropenia in patients with breast cancer.

Breast oncologists react to the availability of granulocyte colony-stimulating factors, used as prophylaxis against chemotherapy-induced neutropenia.

Advantages, in terms of safety and efficacy, of granulocyte colony-stimulating factors used as prophylaxis against chemotherapy-induced neutropenia.

Recommendations for intervening with growth factor support and important considerations for reducing or discontinuing anti-cancer therapy when patients show signs of neutropenia.

Preventive therapies and factors that impact how to best mitigate chemotherapy-induced neutropenia in patients with breast cancer.

Breast oncologists discuss how they weigh the efficacy of anticancer treatment with the possibility of a treatment-related adverse event, like chemotherapy-induced neutropenia.

Recommendations regarding how to best manage patients who experience bone pain from chemotherapy-induced neutropenia prophylaxis with growth factor support.

Considerations regarding the potential to prevent chemotherapy-induced neutropenia with newer therapeutic strategies as well as changes to treatment dosages.

What to know about plinabulin, a first-in-class selective immunomodulating microtubule-binding agent (SIMBA), in preventing chemotherapy-induced neutropenia.

An overview of the design and results of the PROTECTIVE-1 study of plinabulin versus pegfilgrastim in patients with solid tumors receiving docetaxel myelosuppressive chemotherapy.

Implications for treating patients with solid tumor cancers with plinabulin based on quality-of-life data and results demonstrated by the PROTECTIVE-2 trial.

Novel agents under investigation to help address unmet needs in the field of prophylaxis against neutropenia and other toxicities associated with chemotherapies used to treat solid tumors.

A panel of oncologists react to their interest in using plinabulin as prophylaxis against chemotherapy-induced neutropenia in future clinical practice.

An overview of therapies used as prophylaxis against chemotherapy-induced neutropenia and projections on improving quality of life for patients with solid tumors with therapeutic advances.